Marjorie A. Speers, Ph.D., is a global leader in human research protections. Most recently, she was the inaugural president and CEO of the Association for the Accreditation of Human Research Protection Programs, Inc. (AAHRPP), retiring in 2013. Dr. Speers views the opportunity to lead this one-of-a-kind foundation—and continue to contribute to research protections and public well-being worldwide—as the natural progression in an exemplary career of public service. Before establishing AAHRPP in 2001, she served as acting executive director of the National Bioethics Advisory Commission. At the Centers for Disease Control and Prevention, she oversaw research protections for all domestic and international research. Dr. Speers is a graduate of Dickinson College, where she serves on the Board of Trustees and established a scholarship that has benefited numerous international students. She also holds doctoral degrees in psychology and epidemiology from Yale University.
Dr. Katlic serves as chief of the Department of Surgery and surgeon-in-chief at Sinai Hospital, is the director of the Sinai Center for Geriatric Surgery and is the founder of The Aging Surgeon Program. While a resident at the Massachusetts General Hospital, he cared for several 100-year old surgical patients and reviewed the records of other elderly patients publishing his results in 1985 in the Journal of the American Medical Association. He is also an author of five textbooks on geriatric surgery. The Aging Surgeon Program is a comprehensive evaluation of the physical and cognitive functions of older surgeons.
Mark is the Queen's Lead of the £5M Medical Research Council-Cancer Research UK funded Stratified Medicine in Colorectal Cancer Consortium (S:CORT), a UK-wide consortium investigating novel precision medicine approaches in colorectal cancer(CRC). His international reputation in CRC was instrumental in his leading a Critical Gaps in Colorectal Cancer Research Initiative, recently published in the high impact factor journal Gut; this landmark publication has attracted significant global attention (his podcast had the most “hits” of any article in the journal) Mark is Queen's Lead of the Health Data Research UK Substantive Site, one of only 6 in the UK, which aims to drive innovative precision medicine and public health approaches through the use of Big Data. He is also national lead for Cancer Strategy for HDR-UK. Mark was co-chair of the Cancer Task Team of the Clinical Working Group of the Global Alliance for Genomics and Health (GA4GH), an international cooperative dedicated to effective and responsible sharing of genomic and clinical data. He has authored a number of key papers including a blueprint for cancer date sharing (published in Nature Medicine) and a road map/call to action for a Global Cancer Knowledge Network in the New England Journal of Medicine Mark has published over 180 papers in international peer review journals, including key papers in the highest impact journals (New Engl J Medicine, Lancet, Nature Medicine, Lancet Oncology, Cancer Discovery, Nature Comms, Gut etc). He is co-lead of an ambitious proposal to develop a Global Innovation Institute in Belfast which will include the One Health Innovation Centre (OHIC), the world’s first Health and Agri-Food Informatics Innovation Centre. Mark’s work has been recognised by a number of national/international awards including the Vander Molen Prize for Leukaemia Research, the Ely Lilly Prize, the St Lukes Medal for Cancer Research and the Graves Medal for Medical Research. He is frequently invited as a guest speaker to international conferences and sits on a number of high level boards/committees at European level including the European Alliance for Personalised Medicine, the Scientific Board of the European Cancer Patient Coalition and the European Cancer Organisation (ECCO) Oncopolicy Forum Mark has a strong commitment to patient-centred research/care and to addressing cancer inequalities. He was the architect of the European Cancer Patient's Bill of Rights (BoR), a catalyst for change and empowerment tool for cancer patients which he launched in the European Parliament on World Cancer Day 2014. The BoR has been adopted across Europe and led to the 70:35 Vision, 70% survival for all cancer patients in Europe by 2035 which was recently adopted by ECCO, the largest interdisciplinary cancer organisation in Europe. Mark’s advocacy work was instrumental in the recent decision to include boys in national UK HPV vaccination programmes. He is also committed to the provision of optimal pathology and laboratory medicine for citizens in resource-limited settings and was senior author of a recent paper in The Lancet as part of The Lancet Series on Pathology and Laboratory Medicine in Low- and Middle- Income Countries.
Dr. Rupp is a Professor in the Department of Internal Medicine, Section of Infectious Diseases at the University of Nebraska Medical Center. He is the Medical Director of The Nebraska Medical Center Department of Healthcare Epidemiology and co-Director of the Antimicrobial Stewardship Program. Dr. Rupp received his medical degree from Baylor College of Medicine, Houston, Texas and holds a B.S. degree in Chemical Engineering from the University of Texas, Austin, Texas. He underwent internship and residency training in Internal Medicine at Virginia Commonwealth University and completed a Fellowship in Infectious Diseases at VCU. He is a Diplomate, American Board of Internal Medicine, and in the subspecialty area of Infectious Diseases. He is a Fellow of the Society for Hospital Epidemiology of America (SHEA), American College of Physicians (ACP), and the Infectious Diseases Society of America (IDSA). He is a Past-President of SHEA and is a past-president of ASM Division L (Infection Control/Hospital Epidemiology). Dr Rupp has served as a consultant for the US Food and Drug Administration as well as the Centers for Disease Control and Prevention. Dr. Rupp has published over 300 articles, chapters and abstracts and is the editor of a textbook entitled “Biofilms, Infections, and Antimicrobial Therapy.” He frequently presents papers at national and international meetings, serves as a guest lecturer, and is an active teacher and researcher. Dr. Rupp’s research interests are in the areas of staphylococcal disease, healthcare-associated infections, and antimicrobial resistance.
Chair and Professor of PsychologyBinghamton University, State University of New York
Marriage, Intimacy, Dating, Sex, Couples, family studies
Population Health ExpertAnn and Robert H. Lurie Children's Hospital of Chicago
Child Health, Population Health, Child Health Policy, Medicaid, Vaccines, Lead Poisoning, Violence
Matthew Davis, MD, MAPP, is Division Head of Academic General Pediatrics and Primary Care at Ann & Robert H. Lurie Children’s Hospital of Chicago and Associate Chief Research Officer for Health Services and Policy Research at Stanley Manne Children's Research Institute at Lurie Children’s. He is a Professor of Pediatrics at Northwestern University Feinberg School of Medicine. His research focus is on population health, with particular emphasis on the family context and impact of local, state and federal policies on child and family health. Before coming to Lurie Children’s, Dr. Davis was at C.S. Mott Children’s Hospital in Michigan, where he was quoted often in the media as the expert on the impact of the Flint, Michigan water contamination crisis.
Environent, Environmental Economics, environmental economist, climate change action, China Economy, War, Sustainability, Urban Development, 21st century warming, Cities, microeconomics, urban development pollution
Matthew E. Kahn is the Bloomberg Distinguished Professor of Economics and Business at Johns Hopkins University and the Director of JHU's 21st Century Cities Initiative . He is a research associate at the National Bureau of Economic Research and a research fellow at IZA. He has taught at Columbia, the Fletcher School at Tufts University, UCLA and USC. He has served as a Visiting Professor at Harvard and Stanford and as the Low Tuck Kwong Distinguished Visiting Professor at the National University of Singapore. He is a graduate of Hamilton College and the London School of Economics. He holds a Ph.D. in Economics from the University of Chicago. He is the author of Green Cities: Urban Growth and the Environment (Brookings Institution Press 2006) and the co-author (joint with Dora L. Costa) of Heroes and Cowards: The Social Face of War (Princeton University Press 2009). He is also the author of Climatopolis (Basic Books 2010) and Blue Skies over Beijing: Economic Growth and the Environment in China (joint with Siqi Zheng published by Princeton Press in 2016). He has also published three other Amazon Kindle books on urban economics and microeconomics. His research focuses on urban and environmental economics.
Melanie Brasher is an assistant professor of sociology at the University of Rhode Island. She holds a master's and Ph.D. from Duke University. She is a demographer and expert in population aging whose research includes unintended births and health. She is particularly interested in the impact of economic disparities, social support, and community context on the health and well being of older adults in China. As a grad student at Duke, she was a National Institute on Aging pre-doctoral trainee for social and medical demography of aging. She also served as a visiting scholar at the Chinese Center for Disease Control and Prevention in Beijing in 2011, and continues to collaborate with public health researchers on investigations of risk factors and health among elderly Chinese.
Meng Zhu is an associate professor at the Johns Hopkins Carey Business School and specializing in marketing and consumer decision-making. She joined the Carey Business School after receiving her PhD from Carnegie Mellon University. Her research interests include consumer judgment and decision-making, contextual influences on preference construction, the causes of and solutions to inefficiency and inequality, and the impact of marketing cues and comparison standards.
I practice obstetrics, specializing in maternal fetal medicine. This includes treatment of preeclampsia and other problems that can occur during pregnancy. I also treat women experiencing preterm labor and those who have a history of adverse pregnancy outcomes. Patient-centered care is important to me. In obstetrics, there can be gray areas in approaches to treatment. It is important that healthcare decisions be made as a team with the patient and family as key and essential parts of this team. Something many people don't know about me is that, during my career as a Navy physician, I was deployed and provided care in Haiti, Afghanistan and Central America.
Michael Giberson is an associate professor of practice in the Jerry S. Rawls College of Business at Texas Tech University. He is an expert in the areas of energy economics, U.S. energy policy and the electric power industry. Giberson's research and writing focuses on U.S. energy policy and electric power markets, and on the law and economics of price gouging. He is a faculty affiliate at the Free Market Institute at Texas Tech University. Prior to joining Texas Tech in 2008 he worked with Potomac Economics, Ltd., an economic consulting firm specializing in the electric power industry. Michael Giberson has been published in Nature Energy, the Electricity Journal, the Journal of Regulatory Economics, the Pacific and Asian Journal of Energy, and Regulation magazine, and has written on U.S. energy policies and federal electric power issues for trade publications. He is co-author with Lynne Kiesling of the Knowledge Problem blog discussing economics, energy policy, technology and many other topics. Energy posts at Knowledge Problem are included at Social Media Today's The Energy Collective online community. In addition, his commentary and analysis has appeared at Alternative Energy Stocks and MasterResource. Giberson earned his bachelor's degree in economics from Texas Tech and his master's and doctorate degrees in economics from George Mason University.
Sickle Cell Disease, Hemophilia, Blood Cancer, Blood Disease
Modupe Idowu, MD, treats patients with sickle cell anemia, myeloproliferative neoplasm, thrombotic disorders, and hematologic malignancy including lymphoproliferative disorders, plasma cell dyscracias, and leukemias. Her research interests in clinical and translational investigations involve sickle cell anemia and thrombotic disorders. She is the medical director of the UT Physicians Comprehensive Sickle Cell Center.
Triple board-certified in internal medicine, hematology and medical oncology, Dr. Mohamad Cherry is medical director of Hematology at Atlantic Health System Cancer Care. He joined Atlantic Hematology Oncology from the University of Oklahoma Health Sciences Center's Stephenson Cancer Center, bringing years of clinical knowledge and expertise. With specialty training from some of the nation's most skilled clinicians, Dr. Cherry attained some of his clinical training at the leukemia department at MD Anderson and his fellowship in hematology/oncology from the University of Oklahoma Health Sciences Center's Stephenson Cancer Center. He performed two residencies - an internal medicine residency at Staten Island University Hospital and a laboratory medicine residency at the American University of Beirut Medical Center in Lebanon. Previously, Dr. Cherry attained his medical degree at Lebanese University and performed his internship at Sacre Coeur Hospital-Lebanese University. He also earned a master of science degree in clinical and translational research from University of Oklahoma College of Public Health. Dr. Cherry remains on staff as clinical associate professor of hematology/oncology at University of Oklahoma Health Sciences Center's Stephenson Cancer Center. He is also the director of its hematology/oncology fellowship program and co-chairs the Academy of Teaching Scholars Faculty Development, Education and Mentoring Committee. Other administrative roles include co-chair of the leukemia working group at the Sarah Cannon Research Institute Blood Cancer Consortium. As a principal investigator of multiple clinical trials, Dr. Cherry has performed groundbreaking research in niche areas that include epigenetics and development of new therapeutics in relapsed and refractory blood cancers. He has developed teaching materials and book chapters, and has lectured both nationally and internationally. Dr. Cherry continues to serves as a mentor and an advisor to fellows, residents and medical students. He contributes to continuing education, public health, and professional development, and has won awards and funding for both his research and his clinical pursuits.